Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

BioGenes Launches Enhanced Generic HCP Assay

Published: Wednesday, September 18, 2013
Last Updated: Wednesday, September 18, 2013
Bookmark and Share
CHO|360-HCP ELISA for early stage biologics production.

BioGenes GmbH has announced that it has launched a new generic HCP assay with enhanced HCP recovery properties.

The CHO|360-HCP ELISA is designed to cover the broadest possible spectrum of antigens by integrating four different assay types.

An upfront feasibility test will identify the most suitable ELISA kit thus allowing to greatly increasing HCP recovery.

CHO|360-HCP ELISAs employ antibodies of HCPs from different species. By immunizing rabbits and goats with HCPs of a non-transfected CHO cell line combined with a unique approach for antigen and antibody preparation as well as an optimized purification strategy, BioGenes has developed a panel of four different HCP ELISAs that altogether build up the enhanced generic CHO|360-HCP Assay.

Dagmar Schwertner-Knoll, Marketing Director of BioGenes GmbH said: “Our strategy is to offer different ELISA kits for HCP detection. An upfront feasibility test, performed by the customer or by BioGenes as a service, enables the selection of the most suitable kit for a specific process and greatly increases the HCP recovery for most samples.”

For all four assay types the lower limit of detection (LOD) is between 0.5–1 ng/ml and the lower limit of quantification (LOQ) is 2–3 ng/ml with a working range between 2–100 ng/ml.

A high specificity for the antigen in all four assays was determined by 2D western blotting with the respective antibodies.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

BioGenes Reports Strong Growth of HCP Assay Development Business
Company is developing pre-optimized HCP assay kits.
Thursday, February 28, 2013
BioGenes to Develop Specific HCP Assay for Boehringer Ingelheim
HCP assays usually required in clinical phase III studies to demonstrate consistency of manufacturing.
Friday, June 15, 2012
BioGenes Has Developed Cellmid’s Midkine Blood Test and Reports Manufacture of First Kits
BioGenes GmbH, a supplier of GMP compliant immunoassay and antibody services, has developed and optimized the first ever fully validated ELISA protocol for Midkine detection in blood serum.
Tuesday, November 16, 2010
Scientific News
Developing Drug Resistance may be a Matter of Diversity for Tuberculosis
Researchers have probed the bacteria that causes tuberculosis, Mycobacterium tuberculosis, to learn more about how individual bacterial cells change and adapt while in the human body.
Surprising Trait Found in Anti-HIV Antibodies
Scientists at The Scripps Research Institute (TSRI) have new weapons in the fight against HIV.
Some Gut Microbes May Be Keystones of Health
University of Oregon scientists have found that strength in numbers doesn’t hold true for microbes in the intestines. A minority population of the right type might hold the key to regulating good health.
Essential Component of Antiviral Defense Identified
Infectious disease researchers at the University of Georgia have identified a signaling protein critical for host defense against influenza infection.
Single Vaccine for Chikungunya, Related Viruses May be Possible
What if a single vaccine could protect people from infection by many different viruses? That concept is a step closer to reality.
Is Allergy the Price We Pay for Our Immunity to Parasites?
New findings help demonstrate the evolutionary basis for allergy.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
Mucus – the First Line of Defence
Researchers reveal the important role of mucus in building a good defence against invaders.
Antibody Targets Key Cancer Marker
University of Wisconsin-Madison researchers have created a molecular structure that attaches to a molecule on highly aggressive brain cancer and causes tumors to light up in a scanning machine.
Gene-Edited Immune Cells Treat ‘Incurable’ Leukaemia
A new treatment that uses ‘molecular scissors’ to edit genes and create designer immune cells programmed to hunt out and kill drug resistant leukaemia has been used at Great Ormond Street Hospital (GOSH).

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos